Key facts
- It has raised $50.0M; the latest was Early Stage VC ($30.0M) in Jun 2024.
- Notable investors include Shunwei Capital, CDH Investments, 5Y Capital, Sky9 Capital, Lapam Capital — 9 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for ReviR Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for ReviR Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ReviR Therapeutics
Developer of RNA therapeutics intended to treat cancer, rare genetic disorders, and infectious diseases. The company develops an artificial intelligence-based and computation-empowered platform to discover RNA-targeting therapeutics, enabling healthcare personnel to deliver transformative therapies for millions of patients.
- Sector
- Healthcare
- HQ
- Brisbane, CA, United States
- Founded
- 2021
- Employees
- 20
- Website
- revirtx.com/
- Ownership
- Privately Held (backing)
ReviR Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ReviR Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ReviR Therapeutics in its N-PORT filings yet. We sweep new filings monthly.